

## CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number  
WO 2004/055009 A1

(51) International Patent Classification<sup>7</sup>: C07D 403/12, 403/14, 401/12, 401/14, 413/14, A61K 31/497, 31/496, 31/5377, A61P 25/00, 3/10, 5/48, 15/18, 17/14

(21) International Application Number:  
PCT/SE2003/001957

(22) International Filing Date:  
15 December 2003 (15.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0203753-9 17 December 2002 (17.12.2002) SE

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).


(72) Inventors; and

(75) Inventors/Applicants (for US only): BERG, Stefan [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). HELLBERG, Sven [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). SÖDERMAN, Peter [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: AstraZeneca AB; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(54) Title: NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3



active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3.

(57) Abstract: The present invention relates to new compounds of formula (I) wherein Z is N; Y is CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>, CH<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>, NR<sup>5</sup>CONR<sup>5</sup>, CH<sub>2</sub>CO, CO, O or CH<sub>2</sub>O; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing one or more atoms selected from C, N, O or S; Q is C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>alkynyl, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically

A1

WO 2004/055009